History of Weight Loss Medications: 80 Years of Progress, Setbacks, and What Patients Should Know in 2026

The Short Answer

Weight loss medications in the United States have been prescribed for more than 80 years, and nearly every major class has followed the same arc: enthusiastic adoption, mass prescription, then partial or complete withdrawal once long-term safety data emerged. Amphetamines fell to addiction concerns in the 1970s. Fen-Phen was pulled in 1997 over heart valve damage. Ephedra was banned in 2004. Sibutramine (Meridia) was withdrawn in 2010 over cardiovascular risk. Belviq was pulled in 2020 over cancer risk.

Today's leading class — GLP-1 receptor agonists like Ozempic, Wegovy, Mounjaro, and Zepbound — has shown real benefits for blood sugar control and weight reduction, but long-term safety questions (thyroid cancer risk, muscle wasting, gastroparesis) are still being studied and will not be fully answered for several more years.

The clinical lesson, repeated for eight decades: medications can support weight loss, but they rarely succeed without a foundation of healthier eating habits and lifestyle change — and patients should be cautious about pharmacological solutions whose long-term safety profile is still maturing.

Key Takeaways

• Pattern repeats: Every major weight loss drug class has followed a cycle of rapid adoption followed by safety-driven withdrawal — often a decade after launch.

• Major withdrawals: Fen-Phen (1997, heart valves), Ephedra (2004, cardiovascular events), Sibutramine/Meridia (2010, heart attack/stroke), Lorcaserin/Belviq (2020, cancer).

• Currently available: Phentermine (short-term), Orlistat (Xenical, Alli), and the GLP-1 class (Ozempic, Wegovy, Mounjaro, Zepbound, Saxenda).

• GLP-1 unknowns: Long-term effects including thyroid cancer risk and sarcopenia (muscle wasting) remain under active investigation.

• Surgery comparison: Bariatric surgery has 30+ years of long-term data and demonstrates more durable outcomes for clinically obese patients than any pharmacological intervention to date.

Why This History Matters in 2026

Patients walking into a bariatric consultation in 2026 are doing so in the middle of the largest weight loss medication boom in American history. Demand for GLP-1 injectables — Ozempic, Wegovy, Mounjaro, Zepbound — has reached unprecedented levels, with prescription volumes that make 1990s Fen-Phen prescribing look modest by comparison.

The natural question patients ask is: are these drugs safe?

The honest answer is that nobody — not the FDA, not the manufacturers, not prescribing physicians — knows the full long-term answer yet. What we do know is that every previous generation of weight loss medication asked the same question, received reassuring early answers, and then surfaced significant safety problems years later.

This article walks through that 80-year history not to dismiss modern weight loss medications, which have genuine clinical value for the right patients, but to give patients the historical context they need to make informed decisions in conversation with their physician.

1940s to 1970s: Amphetamines and the First "Diet Pills"

What was prescribed:

• Amphetamine (e.g., Benzedrine)

• "Rainbow pills" — combinations of amphetamines, thyroid hormones, diuretics, and sedatives

How they worked: These early diet pills produced weight loss through central nervous system stimulation and appetite suppression caused by catecholamine release.

Why they were withdrawn: High rates of addiction and abuse led to strict regulation under the Controlled Substances Act of 1970. The FDA mandated removal from many formulations and restricted use due to documented systemic toxicity — including dependence, tachycardia, hypertension, psychosis, and severe sleep disturbances.

The historical takeaway: These medications worked. Patients lost weight. But the systemic and psychiatric toll was unacceptable. The first major lesson of weight loss pharmacology had been delivered: efficacy is not the only measure of a drug's value.

1980s to 1990s: The Fen-Phen Catastrophe

What was prescribed:

• Fenfluramine

• Phentermine

• The combination known as "Fen-Phen"

How they worked: Fenfluramine increased serotonin levels, producing a sense of satiety. Phentermine acted as a stimulant appetite suppressant. Combined, they produced more weight loss than either alone.

Scale of use: In 1996 alone, more than 18 million prescriptions were written for fenfluramine-based products. The drug was a cultural and commercial phenomenon.

Why it was withdrawn: In 1997, fenfluramine and dexfenfluramine were removed from the market following overwhelming evidence linking them to heart valve damage and primary pulmonary hypertension. The damage was caused by serotonin dysregulation in vascular tissue.

Aftermath: The withdrawal triggered billions of dollars in lawsuits, permanent FDA caution toward weight loss combination therapies, and a fundamental rethinking of post-market surveillance for drugs prescribed to large populations.

The historical takeaway: Long-term safety problems can take a decade or more to surface — and by then, millions of patients may have been exposed.

1990s to 2000s: Fat Blockers, Stimulants, and Supplements

Ephedra (Banned 2004)

A sympathomimetic stimulant with effects similar to amphetamines, marketed widely as a dietary supplement. The FDA banned ephedra in 2004 after overwhelming reports of heart attacks, strokes, and sudden death linked to its use.

Sibutramine (Meridia)

Approved in 1997 as a serotonin and norepinephrine reuptake inhibitor, Sibutramine was prescribed for over a decade before long-term cardiovascular trials revealed an increased risk of heart attack and stroke. It was removed from the global market in 2010.

Orlistat (Xenical, Alli)

Approved in 1999, Orlistat works by inhibiting intestinal fat absorption. It remains FDA-approved and available today in both prescription (Xenical) and over-the-counter (Alli) formulations. Its safety profile is acceptable, but its use has declined sharply due to gastrointestinal side effects — including oily stools, fecal urgency, and flatulence — which patients find difficult to tolerate.

2000s to 2010s: New Mechanisms, New Failures

Rimonabant (Acomplia)

A cannabinoid receptor antagonist approved in Europe in 2006. It was never FDA-approved in the United States. Rimonabant was withdrawn globally in 2008 after being linked to severe psychiatric side effects, including depression and suicidal ideation.

Lorcaserin (Belviq)

A serotonin 2C receptor agonist approved by the FDA in 2012. It was withdrawn from the market in 2020 after a long-term post-market safety trial revealed an increased incidence of cancer in patients taking the drug.

Phentermine-Topiramate (Qsymia) and Naltrexone-Bupropion (Contrave)

Both combination medications were approved in the early 2010s and remain available today. Their use is limited compared to the GLP-1 class, primarily due to a less favorable side effect profile and a more modest efficacy ceiling.

2010s to Present: The GLP-1 Revolution

The current era of weight loss pharmacology is dominated by GLP-1 receptor agonists — medications originally developed for Type 2 diabetes that have demonstrated significant weight loss as a secondary effect. This class has produced the most clinically meaningful weight reduction of any pharmacological intervention to date, and it has done so with a side effect profile that — at least in the short and medium term — appears acceptable to most patients.

The class is large, and the brand names are now widely recognized.

Currently Available GLP-1 Receptor Agonists

Semaglutide (Injectable and Oral)

• Ozempic — weekly injection, FDA-approved for Type 2 diabetes

• Wegovy — weekly injection, FDA-approved for chronic weight management

• Rybelsus — daily oral tablet, FDA-approved for Type 2 diabetes

Tirzepatide (Dual GLP-1 / GIP Agonist, Injectable)

• Mounjaro — weekly injection, FDA-approved for Type 2 diabetes

• Zepbound — weekly injection, FDA-approved for chronic weight management

Liraglutide (Injectable)

• Victoza — daily injection, FDA-approved for Type 2 diabetes

• Saxenda — daily injection, FDA-approved for chronic weight management

Dulaglutide (Injectable)

• Trulicity — weekly injection, FDA-approved for Type 2 diabetes

Exenatide (Injectable)

• Byetta — twice-daily injection, FDA-approved for Type 2 diabetes

• Bydureon BCise — weekly extended-release injection, FDA-approved for Type 2 diabetes

Lixisenatide (Injectable)

• Adlyxin — daily injection, FDA-approved for Type 2 diabetes

How GLP-1 Receptor Agonists Work in the Body

These medications produce weight loss and blood sugar control through three primary mechanisms:

Pancreatic effects (blood sugar control): GLP-1 receptor agonists bind to receptors on pancreatic beta-cells, prompting insulin secretion. They also reduce glucagon release from alpha-cells, stabilizing glucose levels.

Appetite and satiety (weight loss): GLP-1 receptors in the hypothalamus are activated, producing reduced hunger.

Delayed gastric emptying: These medications slow the rate at which the stomach empties, contributing to a sustained feeling of fullness — and producing many of their characteristic gastrointestinal side effects.

Documented Side Effects of GLP-1 Receptor Agonists

Common Gastrointestinal Effects

• Nausea — affects up to 50% of users, typically during the initial treatment phase

• Diarrhea and vomiting — frequently reported; diarrhea affects roughly one-third of users

• Constipation — common, particularly with long-term use

• Abdominal distention, pain, and dyspepsia — caused by delayed gastric emptying. Can progress to clinically significant gastroparesis, where the stomach does not contract normally and food may sit for half a day or longer

• Acid reflux — delayed gastric emptying places additional pressure on the lower esophageal sphincter, allowing stomach contents to reflux into the esophagus. This can cause cough, sinus problems, nasal congestion, and other "silent" reflux symptoms that patients may not associate with the medication

Other Common Side Effects

• Injection site reactions — mild itching, redness, or swelling

• Headaches and dizziness — reported by some users

• Hypoglycemia (low blood sugar) — primarily in patients also taking insulin or sulfonylureas

• "Ozempic Face" — a saggy or hollow facial appearance attributed to rapid weight loss rather than direct drug toxicity

• Sarcopenia (muscle wasting) — significant reduction in muscle tone and mass when patients lose weight rapidly without adequate protein intake or resistance training

Psychiatric Side Effects

• Anxiety

• Depression

Rare but Serious Side Effects

• Pancreatitis — inflammation of the pancreas, sometimes severe

• Acute kidney injury — sometimes related to dehydration from vomiting or diarrhea

• Gallbladder problems — including gallstones and cholecystitis (inflammation or infection of the gallbladder), which can present as abdominal pain that may radiate to the back

• Medullary thyroid cancer — there is an FDA-mandated label warning regarding this concern. The relationship is currently under active study and will require several more years of post-market data to fully characterize

How Today's GLP-1 Drugs Compare to Bariatric Surgery

Patients evaluating their options in 2026 are often choosing between long-term GLP-1 therapy and bariatric surgery. Both are legitimate paths, and the right choice depends on the patient's clinical picture, weight, comorbidities, and personal goals.

A few honest comparisons worth noting:

Long-term safety data: Bariatric surgical procedures — particularly gastric sleeve and gastric bypass — have 30+ years of long-term outcomes data. GLP-1 receptor agonists have less than a decade of meaningful weight loss data and an unknown long-term safety profile.

Durability of weight loss: Bariatric surgery typically produces a significant and sustained weight loss for the majority of patients over a 10-year horizon. GLP-1 medications produce a modest weight loss while taken; weight regain is common and often substantial when patients discontinue the medication.

Cost over time: GLP-1 medications carry substantial recurring monthly cost, often exceeding $1,000 per month without insurance coverage — and many insurance plans do not cover them for weight management. Bariatric surgery has a single up-front cost, often covered by insurance for clinically eligible patients.

Patient experience: GLP-1 medications produce ongoing gastrointestinal side effects in a significant percentage of users. Bariatric surgery involves a recovery period followed by lifelong dietary adjustment but does not produce ongoing pharmacological side effects.

For patients in the Jacksonville area considering their options, scheduling a consultation provides the most reliable way to evaluate which approach — medication, surgery, or a combination — is most appropriate given individual medical history.

Final Considerations

Obesity is widely accepted as a chronic and multifactorial disease. It correlates with many other conditions — cardiovascular disease, Type 2 diabetes, sleep apnea, joint disease, and certain cancers — both directly and indirectly tied to excess weight or its associated metabolic changes.

As 80 years of history demonstrates, we have searched continuously for medications that could meaningfully and safely help patients lose weight. Without a foundation of healthier eating habits and lifestyle change, the success of nearly all weight loss approaches is severely compromised.

Medications can aid in weight loss. They can be the right choice for the right patient. But patients and physicians alike should consider the long-term effects when these drugs are used for anything beyond short-term treatment — particularly given that nearly every previous generation of weight loss medication required years of post-market data before its true safety profile was understood.

History has educated us. Several "promising" medications, extensively prescribed in their time, were later limited or withdrawn — for lack of results in some patients, or for side effects ranging from heart valve disease to death.

The patients who do best, in our experience, are those who treat any pharmacological or surgical intervention as one component of a broader, sustainable approach — incorporating nutrition, exercise, behavioral support, and ongoing medical guidance.

Frequently Asked Questions

Are GLP-1 medications like Ozempic, Wegovy, and Zepbound safe for long-term use?

GLP-1 receptor agonists are generally considered acceptably safe for long-term use in carefully selected patients, but multiple long-term safety questions remain unresolved — including thyroid cancer risk (medullary type), muscle mass loss (sarcopenia), and gastrointestinal complications such as gastroparesis. The full long-term safety profile will not be known for several more years of post-market data.

What was Fen-Phen and why was it banned?

Fen-Phen was the combination of fenfluramine and phentermine widely prescribed for weight loss in the 1990s. Fenfluramine was withdrawn from the market in 1997 after being strongly linked to heart valve disease and primary pulmonary hypertension. Over 18 million prescriptions had been written in 1996 alone, and the fallout produced billions of dollars in lawsuits.

Which weight loss medications are still available in the United States in 2026?

Currently FDA-approved weight loss medications include phentermine (short-term use only), orlistat (Xenical, Alli), and the GLP-1 receptor agonist class — Ozempic, Wegovy, Mounjaro, Zepbound, Saxenda, and others.

Why do so many weight loss medications eventually get pulled from the market?

Most weight loss medications throughout history have followed a similar pattern: rapid adoption based on short-term efficacy, followed by long-term safety data revealing serious complications. These have included cardiovascular events (Fen-Phen, Sibutramine, Ephedra), psychiatric effects (Rimonabant), and cancer risk (Lorcaserin/Belviq). Some complications have taken a decade or more to surface in the medical literature.

What are the main differences between Ozempic, Wegovy, Mounjaro, and Zepbound?

Ozempic and Wegovy both contain semaglutide; Ozempic is FDA-approved for Type 2 diabetes, Wegovy for chronic weight management. Mounjaro and Zepbound both contain tirzepatide, a dual GLP-1/GIP agonist; Mounjaro is approved for Type 2 diabetes, Zepbound for chronic weight management. Tirzepatide-based medications generally produce greater weight loss than semaglutide-based medications in clinical trials.

Is medication alone enough to achieve sustained weight loss?

Generally, no. Sustained weight loss in most patients requires a combination of healthier eating habits, physical activity, behavioral support, and — for patients meeting clinical criteria — surgical intervention. Medications can support this process but rarely succeed in isolation, particularly because weight regain is common when most weight loss medications are discontinued.

How does bariatric surgery compare to GLP-1 medications for weight loss?

Bariatric surgery has 30+ years of long-term outcomes data and typically produces more durable weight loss than GLP-1 medications, particularly for patients with clinical obesity. GLP-1 medications produce weight loss while taken, but weight regain is common after discontinuation. The right choice depends on the patient's clinical picture, weight, comorbidities, insurance coverage, and personal preferences.

How can I learn whether I'm a candidate for bariatric surgery in Jacksonville?

Patients in the Jacksonville, North Florida, or South Georgia area can schedule a consultation with Dr. Michael Baptista to discuss their medical history, current health, and the treatment options most appropriate for their situation. The practice can be reached at (904) 724-2263.

About the Author

Dr. Michael Baptista, MD has received training from renowned medical institutions in both Brazil and the USA, including the University of Minnesota, Mayo Clinic, Rush University, and the University of Illinois at Chicago. He has undergone extensive training in general surgery and bariatric surgery, with a focus on minimally invasive techniques. He has performed thousands of weight loss and general surgery procedures and has expertise in various areas including general surgery, stomach surgery, thoracic surgery, and surgical research. He is a published author and experienced educator, Dr. Baptista shares his knowledge through courses and training sessions on bariatric surgery and patient follow-up.

Learn more about Dr. Baptista | View patient success stories | Schedule a consultation | (904) 724-2263

Office: 9471 Baymeadows Road, Suite 207, Jacksonville, FL 32256

This article is provided for educational purposes and reflects the clinical perspective of the author based on currently available medical literature. It does not constitute personal medical advice. Always consult with a qualified healthcare provider before starting, stopping, or modifying any medication or treatment plan. Last reviewed by Dr. Baptista on April 29, 2026.